Meta-analysis of MTHFR 677C→T polymorphism and coronary heart disease:: does totality of evidence support causal role for homocysteine and preventive potential of folate?

被引:233
作者
Lewis, SJ [1 ]
Ebrahim, S [1 ]
Smith, GD [1 ]
机构
[1] Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England
来源
BMJ-BRITISH MEDICAL JOURNAL | 2005年 / 331卷 / 7524期
关键词
D O I
10.1136/bmj.38611.658947.55
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To investigate the association between the MTHFR 677C-->T polymorphism and coronary heart disease, assessing small study bias and heterogeneity between studies. Data sources Medline and Embase citation searches between January 2001 and August 2004; no language restrictions. Study selection Case-control and prospective studies of association between MTHFR 677C-->T variant and myocardial infarction, coronary artery occlusion, or both; 80 studies were included. Data extraction Data on genotype frequency mid mean homocysteine concentrations by genotype were extracted. Odds ratios were calculated for TT genotype versus CC genotype. Heterogeneity was explored, with stratification by geographical region of the study samples, and meta-regression by difference in mean serum homocysteine concentrations (CC minus TT genotypes) was carried out. Results 26 000 cases and 31 183 controls were included. An overall random effects odds ratio of 1.14 (95% confidence intervals 1.05 to 1.24) was found for TT versus CC genotype. There was strong evidence of heterogeneity (P < 0.001, I-2 = 38.4%), which largely disappeared after stratification by geographical region. Odds ratios in Europe, Australia, and North America attenuated towards the null, unlike those in the Middle East and Asia. Conclusions No strong evidence exists to support an association of the MTHFR 677C-->T polymorphism and coronary heart disease in Europe, North America, or Australia. Geographical variability may be due to higher folate intake in North America and Europe or to publication bias. The conclusion drawn from previous meta-analyses that folic acid, through lowering homocysteine, has a role in prevention of cardiovascular disease is in some doubt.
引用
收藏
页码:1053 / 1056A
页数:5
相关论文
共 28 条
[1]  
Abu-Amero KK, 2003, ARCH PATHOL LAB MED, V127, P1349
[2]   Methylenetetrahydrofolate reductase 677C→T genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement:: a randomized controlled trial [J].
Ashfield-Watt, PAL ;
Pullin, CH ;
Whitting, JM ;
Clark, ZE ;
Moat, SJ ;
Newcombe, RG ;
Burr, ML ;
Lewis, MJ ;
Powers, HJ ;
McDowell, IFW .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2002, 76 (01) :180-186
[3]  
Baker F, 2002, CIRCULATION, V106, P741
[4]  
Brattström L, 2000, AM J CLIN NUTR, V72, P315
[5]  
Brattström L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894
[6]  
Casas JP, 2005, LANCET, V365, P224, DOI 10.1016/S0140-6736(05)70152-5
[7]   Commentary: An updated review of the published studies of homocysteine and cardiovascular disease [J].
Clarke, R .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2002, 31 (01) :70-71
[8]   Problems of reporting genetic associations with complex outcomes [J].
Colhoun, HM ;
McKeigue, PM ;
Smith, GD .
LANCET, 2003, 361 (9360) :865-872
[9]   Dose-related association of MTHFR 677T allele with risk of ischemic stroke -: Evidence from a cumulative meta-analysis [J].
Cronin, S ;
Furie, KL ;
Kelly, PJ .
STROKE, 2005, 36 (07) :1581-1587
[10]   Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke - a randomized substudy of the VITATOPS trial [J].
Dusitanond, P ;
Eikelboom, JW ;
Hankey, GJ ;
Thom, J ;
Gilmore, G ;
Loh, K ;
Yi, Q ;
Klijn, CJM ;
Langton, P ;
van Bockxmeer, FM ;
Baker, R ;
Jamrozik, K .
STROKE, 2005, 36 (01) :144-146